Skip to content

Thulium Fiber Laser (TFL) Versus Holmium MOSES Laser for Ureteroscopic Management of Kidney Stones

Thulium Fiber Laser (TFL) Versus Holmium MOSES Laser in Ureteroscopic Management of Kidney Stones 10-20mm: A Randomized Prospective Clinical Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05598645
Enrollment
174
Registered
2022-10-28
Start date
2022-08-16
Completion date
2026-09-30
Last updated
2024-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Stone

Brief summary

This study aims to compare the efficacy and safety of both types of lasers, Holmium MOSES and TFL, in management of kidney stones requiring treatment.

Detailed description

The prevalence of kidney stones has been increasing over the last two decades with lifetime recurrence risk reported to be as high as 50%. Holmium lasers are nowadays considered the gold standard for treatment of urinary tract stones. Recently, the holmium laser urology platform from Lumenis has been updated to include a new technology called MOSES, which provides improved energy delivery of the laser to treat the stones, reduces migration of the stone during the procedure, and limits potential collateral tissue damage. A new generation of lasers has evolved due to the advances in laser fiber technology, leading to the development of the Thulium Fiber Laser (TFL). TFL can operate within a large range of energy, frequency and pulse duration settings. The small fiber size is one of the main advantages of TFL, as it allows better endoscope performance through easier deflection and bigger working channel space. Furthermore, it produces small stone fragments and better dusting capabilities compared to the standard Holmium laser when adjusted on the same power settings. This study will compare the efficacy and safety of Holmium MOSES and TFL in management of kidney stones requiring treatment.

Interventions

Participants will undergo treatment using the TFL

Participants will undergo treatment using the MOSES Holmium laser.

Sponsors

Thunder Bay Regional Health Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. 18 years of age and over at the time of enrollment. 2. Patients referred with single kidney stones of 10-20 mm in its largest diameter, or multiple stones involving a single calyx. 3. Written informed consent to participate in the study 4. Ability to comply with the requirements of the study procedures

Exclusion criteria

1. Patients with ipsilateral distal ureteral stones or stricture. 2. Stone size \> 20 mm or multiple kidney stones in different calyces. 3. Previous shock wave lithotripsy (SWL) treatment for the same stone. 4. Participants with active urinary tract infection until appropriately treated 5. Uncorrected coagulopathy (anticoagulants or blood thinners which cannot be withheld before surgery). 6. Pregnancy. 7. Participants with preexisting conditions, which, in the opinion of the investigator, interfere with the conduct of the study. 8. Participants who are uncooperative or cannot follow instructions. 9. Participants who lack the capacity, or cannot speak English, in order to provide free and informed written consent. 10. Patients with solitary kidney.

Design outcomes

Primary

MeasureTime frameDescription
Procedural TimeIntraoperativeMeasured in number of minutes from the insertion of the ureteroscope to the removal of the ureteroscope.

Secondary

MeasureTime frameDescription
Total operative timeIntraoperativeMeasured in n minutes from the anesthesia induction until placement of the stent.
Lasing timeIntraoperativeMeasured in minutes and defined as the time the laser was in use, not including pedal pauses.
Total energy usedIntraoperativeMeasured in kilojoules, defined as energy used to fragment the stones into small pieces (≤2 mm).
Stone Free Rate (SFR)4 and 12 weeks post-opSRF will be defined as the absence of any residual stone fragments or the presence of clinically insignificant residual stone fragments in the urinary tract which were defined as ˂4 mm, asymptomatic, non-obstructive and non-infectious stone particles.
Number of times the laser pedals are pressedIntraoperativeMeasured as a numerical value, defined as number of left, right, and total pedal presses
Percentage of Patients with Post-op Complications4 weeksPercentage of patients that results with a post-op complication
Laser efficiencyIntraoperativeMeasured as mm per minute and defined as the stone size (mm) that can be treated every minute; the cumulative stone size (adding the maximum size of each stone that is treated during the surgery) is divided by the lasering time.

Countries

Canada

Contacts

Primary ContactShalyn Littlefield, MSc
shalyn.littlefield@tbh.net(807) 684-6000
Backup ContactHazem Elmansy, MD
elmansyh@tbh.net(807) 684-6000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026